Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas (CG118)Product type:GuidanceProgramme:Clinical guidelineLast updated: 20 September 2022Published: 23 March 2011
Computed tomographic colonography (virtual colonoscopy) (IPG129)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 June 2005
Crohn’s disease: management (NG129)Product type:GuidanceProgramme:NICE guidelinePublished: 3 May 2019
Darvadstrocel for treating complex perianal fistulas in Crohn’s disease (TA556)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 January 2019
Endo-SPONGE for treating low rectal anastomotic leak (MTG63)Product type:GuidanceProgramme:Medical technologies guidancePublished: 16 December 2021
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 March 2024
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Extracorporeal photopheresis for Crohn's disease (IPG288)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 February 2009
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)Product type:GuidanceProgramme:Diagnostics guidancePublished: 2 October 2013
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 June 2022
Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years TS ID 11959Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 February 2015
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 May 2010
Infliximab for acute exacerbations of ulcerative colitis (TA163)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 December 2008
Leukapheresis for inflammatory bowel disease (IPG126)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 June 2005
Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 October 2023
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 October 2022
Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)Product type:AdviceProgramme:Medtech innovation briefingPublished: 4 December 2017
PredictSURE IBD and IBDX to guide treatment of Crohn’s disease (DG45)Product type:GuidanceProgramme:Diagnostics guidancePublished: 23 February 2022
PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)Product type:AdviceProgramme:Medtech innovation briefingPublished: 10 January 2023
ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)Product type:AdviceProgramme:Medtech innovation briefingPublished: 12 July 2022
Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis (ES35)Product type:AdviceProgramme:Evidence summaryPublished: 24 February 2021
RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)Product type:AdviceProgramme:Medtech innovation briefingPublished: 20 June 2017
Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 May 2023
Risankizumab for treating moderately to severely active ulcerative colitis (TA998)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2024
SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (DG44)Product type:GuidanceProgramme:Diagnostics guidancePublished: 17 November 2021
Teduglutide for treating short bowel syndrome (TA804)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 June 2022
Therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (DG22)Product type:GuidanceProgramme:Diagnostics guidancePublished: 17 February 2016
Tofacitinib for moderately to severely active ulcerative colitis (TA547)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 November 2018
Ulcerative colitis: management (NG130)Product type:GuidanceProgramme:NICE guidelinePublished: 3 May 2019
Upadacitinib for previously treated moderately to severely active Crohn’s disease (TA905)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 June 2023
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 January 2023
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment (TA456)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 July 2017
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 June 2020
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) (TA826)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 September 2022
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 August 2015
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 June 2015